Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3

Watchlist Manager
Ouro Fino Saude Animal Participacoes SA Logo
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Watchlist
Price: 22.47 BRL -0.97% Market Closed
Market Cap: 1.2B BRL
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one OFSA3 stock under the Base Case scenario is 80.99 BRL. Compared to the current market price of 22.47 BRL, Ouro Fino Saude Animal Participacoes SA is Undervalued by 72%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OFSA3 Relative Value
Base Case
80.99 BRL
Undervaluation 72%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.2
P/S
P/S
Price to Sales
1.2
vs History
79
vs Industry
68
Median 3Y
1.2
Median 5Y
1.3
Industry
2.4
Forward
1
More Details
1.5
P/E
P/E
Price to Earnings
1.5
vs History
77
vs Industry
45
Median 3Y
10
Median 5Y
11.9
Industry
20.3
Forward
10.5
More Details
16.3
P/OCF
P/OCF
Price to OCF
16.3
vs History
49
vs Industry
28
Median 3Y
13.3
Median 5Y
16.3
Industry
15.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
31
Median 3Y
7.6
Median 5Y
12
Industry
23.1
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
74
vs Industry
47
Median 3Y
1.7
Median 5Y
1.9
Industry
2
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
77
vs Industry
68
Median 3Y
1.3
Median 5Y
1.4
Industry
2.5
Forward
1
More Details
2.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.4
vs History
87
vs Industry
67
Median 3Y
2.7
Median 5Y
2.9
Industry
4.8
More Details
1.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
1.4
vs History
92
vs Industry
52
Median 3Y
7.2
Median 5Y
7.9
Industry
12.5
Forward
5
More Details
1.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
1.4
vs History
92
vs Industry
50
Median 3Y
9
Median 5Y
9.6
Industry
15.7
Forward
5.9
More Details
17
EV/OCF
EV/OCF
Enterprise Value to OCF
17
vs History
52
vs Industry
27
Median 3Y
13.9
Median 5Y
17.6
Industry
14.1
More Details
42.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
42.9
vs History
28
vs Industry
13
Median 3Y
10.3
Median 5Y
18.9
Industry
17.6
More Details
1.3
EV/IC
EV/IC
Enterprise Value to IC
1.3
vs History
68
vs Industry
50
Median 3Y
1.3
Median 5Y
1.4
Industry
1.8
More Details

Multiples Across Competitors

OFSA3 Competitors Multiples
Ouro Fino Saude Animal Participacoes SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
BR
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
1.2B BRL 1.2 1.5 1.4 1.4
US
Eli Lilly and Co
NYSE:LLY
734.6B USD 15 66.1 35.5 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.6B USD 4.2 17 12.5 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.7 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
215.9B CHF 3.6 26.1 9.8 11.4
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP 4 28.5 130.9 197.4
CH
Novartis AG
SIX:NOVN
182.1B CHF 4.1 17.2 10.1 13.6
US
Merck & Co Inc
NYSE:MRK
199.8B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
120.1B EUR 1.3 9.5 5.2 6.1
P/E Multiple
Earnings Growth PEG
BR
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Average P/E: 21.9
1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.1
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28.5
36%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.5
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
BR
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Average EV/EBITDA: 394
1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
CH
Novartis AG
SIX:NOVN
10.1
5%
2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
BR
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Average EV/EBIT: 1 697
1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
197.4
21%
9.4
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.1
14%
0.4

See Also

Summary
OFSA3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
OFSA3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OFSA3 stock valuation using valuation multiples.
Wall Street Estimates
OFSA3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OFSA3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.